TGA – Brexit – Implications for therapeutic goods in Australia
Published in Brexit and Therapeutic Goods Administration - TGA
More from BrexitMore posts in Brexit »
- UK – Medicines and Medical Devices Bill: overarching documents
- Ireland – HPRA update – Brexit Transitional Period: Implications for Medicine and Medical Device Companies up to 31 December 2020
- From RAPS – UK Introduces Medicines, Medical Devices Bill in Post-Brexit Overhaul
- UK – Future of UK Life Sciences: how to reshape the industry for the 2020s (from The Economist)
- Update from GOV.UK – Regulating medical devices in the event of a no-deal Brexit – UK Responsible Person
More from Therapeutic Goods Administration - TGAMore posts in Therapeutic Goods Administration - TGA »
- Australia – TGA – 3-D printing (additive manufacturing) of medical devices
- Australia – TGA – Actual and potential harm caused by medical software
- TGA – Regulation impact statement: Proposed regulatory scheme for personalised medical devices, including 3D-printed devices
- TGA – Medical device application processing times
- TGA guidance – Researcher considerations for medical devices Meeting the evidence requirements for market authorisation
Be First to Comment